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Crosstalk between ARF6 and protein kinase C in FcRI-mediated
activation of phospholipase D1
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Fc receptors play a pivotal role linking the cellular the mechanisms regulating receptor coupling to PLD in
intact cells where the components are endogenously ex-and humoral arms of the immune system [1–3]. Our
previous studies have shown that the human high- pressed and functional. First, the presence of specific
PLD isozymes in the cell membrane fraction was exam-affinity immunoglobulin G receptor FcRI couples
to a novel intracellular signaling pathway requiring ined following receptor aggregation over time, using an
established protocol [8]. In resting cells, only low levelsphospholipase D activation [4]. The mechanisms
that regulate receptor coupling to phospholipase D of immunoreactive PLD were found in the nuclear-free
membrane fraction. The majority of immunoreactivein intact cells are poorly understood but involve
small molecular weight GTPases and protein kinase PLD1 activity was found in the “nuclear” rich fraction
which contains the triton-insoluble cytoskeleton (FigureC [5–7]. Here, we show that immune complex
aggregation of FcRI stimulates the association of 1a) [9]. Immune complex activation of FcRI resulted in
the rapid appearance of immunoreactive PLD1, corre-phospholipase D1 with ARF6 and protein kinase C.
Surprisingly, PKC activity per se is not required. sponding to the splice variant PLD1a within the nuclear-
free membrane fraction (Figure 1a) [10]. No immunoreac-Rather, all of the FcRI-mediated increase in PKC
activity requires phospholipase D1, as treatment of tivity for PLD1b or PLD2was observed in this membrane
fraction in resting cells or at any time point after FcRIcells with butan-1-ol (0.3%) or specific
downregulation of phospholipase D1 using activation (data not shown).
antisense oligonucleotides inhibits FcRI-coupled
PKC activation. Moreover, treatment of cells with The regulation of PLD1 activity is complex. Phosphati-
butan-1-ol or phospholipase D1 antisense dylinositol-4,5-bis-phosphate is an absolute requirement
oligonucleotides inhibits translocation of PKC, -, for activity. There is also clear evidence in vitro for the
and - but had no effect on the association of PKC regulation of PLD1 by ARF1, Rho, and the regulatory
or ARF6 with phospholipase D1. These data indicate domain of either PKC or PKC [5, 11]. However, ex-
that association with ARF6 and PKC plays a role tending these observations to intact cells has proved diffi-
in coupling FcRI to phospholipase D1 activation cult, as studies have depended on heterologous overex-
and that PLD1 lies upstream of all FcRI-mediated pression of various components combined with the use
PKC activity. of inhibitors to explore the pathways [6, 12–15]. To deter-
mine the role of these various activators in regulating the
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for ARF6 and foundARF6 immunoreactivity in the PLD1
immunoprecipitates but only after FcRI aggregation
(Figure 1b). This data indicates that aggregation of FcRI
results in the association of PLD1 with ARF6 and PKCResults and discussion
Functional coupling of FcRI activation by immune com- but not ARF1–5 or Rho. The time course of the associa-
tion of PLD1 to ARF6 was similar to that observed forplexes to phospholipase D (PLD) has previously been
demonstrated in interferon- (IFN-)-primed U937 cells PKC and strongly suggests that both these proteins are
involved in coupling FcRI activation to PLD1.[4], and, here, this pathway has been exploited to explore
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Figure 1
Coupling of FcRI to PLD activation results in the appearance of typical from three separate experiments. (b) Immunoprecipitation of
PLD1a in the nuclear-free membrane fraction and the specific PLD1 demonstrates FcRI aggregation triggered association of PLD1
association of PLD1a with PKC and ARF6 but not Rho or ARF1–5. with PKC and ARF6. Following aggregation of FcRI, cells were
(a) Western blot analysis of PLD1 immunoprecipitated from the harvested at given time points, lysed, and PLD1 was immunoprecipitated
nuclear (Triton X-100 insoluble) and nuclear-free membrane (Triton from these whole-cell lysates. These immunoprecipitates were
soluble) fractions following FcRI aggregation in IFN--primed U937 electrophoresed through 12% acrylamide, and, following transfer
cells. Numbers refer to the time after activation of FcRI. Both fractions to nitrocellulose, the blots were probed for the presence of either
were also probed for the presence of actin. The results shown are PKC or ARF6, using specific monoclonal antibodies.
Our finding here that ARF6 associates with PLD1 is con- letional analysis has demonstrated that the amino-termi-
nal region of PLD1 is required for this direct activationsistent with emerging evidence that points to a role for
ARF6 and not ARF1 as the factor that regulates PLD1 by PKC, presumably through protein:protein interac-
tions [6]. Here, we have shown for the first time a physicalin intact cells [16]. However, the absence of Rho in this
study is surprising, as this factor has previously been con- association of PLD1 and PKC following receptor activa-
tion in intact cells.sidered themajor factor involved in regulating PLD1. Rho
has been proposed to synergize with PKC to maximally
stimulate PLD1 by G protein-coupled receptors and to This association of PKC with PLD1 was independent
synergize with ARF during fMLP and muscarinic signal- of either PKC kinase activity or the generation of phos-
ing [6, 12, 14, 15]. These previous reports studied recep- phatidic acid by PLD activity, as pretreating cells either
tors that are seven-transmembrane domain receptors. In with PKC inhibitors, bisindolymaleimide I (50 nM) or
this study, FcRI is an immune receptor that is coupled Ro-31-8220 (50 nM), two different PKC inhibitors, or with
to signaling cascades through the activation of soluble 0.3% butan-1-ol had no effect on this association (data
tyrosine kinases by the recruitment of the immunorecep- not shown). Furthermore, FcRI-stimulated PLD activity
tor tyrosine activation motif of the  chain [17]. It is was found to be upstream of PKC activity. Thus, in cells
possible that the previously reported critical role of Rho treated with bisindolymaleimide I (50 nM) or Ro-31-8220
is a feature for seven-transmembrane receptors and that (50 nM), FcRI activation of PLD was completely unaf-
Rho plays a lesser role in coupling receptors that signal fected, even at concentrations which completely ablated
through tyrosine kinases. the normal rise in PKC (Figure 2a,b). Despite the lack of
effect of kinase inhibitors, PKC is required for receptor
coupling to PLD activation, as downregulation of PKCThe relationship of PKC to the activation of PLD has
been controversial. Phorbol esters are widely used to acti- by either phorbol esters or specific antisense treatment
reduced the ability of FcRI to activate PLD (Figurevate PLD in cells, and the PKC inhibitor calphostin C
inhibits activation of PLD. However, as calphostin C has 2c,d). We have previously shown that U937 cells are sensi-
tive to antisense manipulation [17]. Taken together, theserecently been reported to directly inhibit PLD, this has
cast doubt on these observations [6]. In vitro studies have data indicate that both the association of PKC with
PLD1 and the measured increase in PLD activity aftershown that PKC activates PLD1 through its regulatory
domain in a nucleotide-independent manner [6, 11]. De- receptor aggregation depend on PKC but is independent
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Figure 2
PLD activation by FcRI is independent of PKC kinase activity but results from at least three separate experiments. (c) Downregulation
dependent on association with PKC. (a) Preincubation of cells of PKC by chronic treatment with phorbol esters abolishes
with either bisindolylmaleimide I (Bis) or Ro-31-8220 (Ro) inhibits the activation of PLD1 by FcRI. PLD activity was measured in cells
activation of protein kinase C, following FcRI aggregation. Cells were following aggregation of FcRI and was compared to basal levels.
pretreated with bisindolylmaleimide I (Bis), 50 nM, or Ro-31-8220 Control cells, cells not treated with phorbol esters; o/n PMA, cells
(Ro), 50 nM, for 30 min prior to receptor aggregation. PKC activity treated overnight with 10 nM PMA; Basal, basal levels of PLD activity
was measured at the time points after FcRI aggregation as indicated in cells where FcRI is not aggregated; XL, PLD activity in cells
[8]. XL control, FcRI aggregated in cells not treated with either following FcRI receptor aggregation. (d) Specific downregulation
inhibitor. Results are the mean  SD for triplicate measurements and of PKC using antisense oligonucleotides reduces the ability of FcRI
are representative of results from at least three separate experiments. to activate PLD. PLD activity was measured in cells following
(b) Preincubation of cells with either bisindolylmaleimide I (Bis) or Ro- aggregation of FcRI and was compared to basal levels. Control cells,
31-8220 (Ro) has no effect on PLD activation following aggregation cells treated with control scrambled oligonucleotide; as PKC, cells
of FcRI. Cells were pretreated with bisindolylmaleimide I (Bis), 50 treated with specific antisense oligonucleotide to PKC; Basal, basal
nM, or Ro-31-8220 (Ro), 50 nM, for 30 min prior to receptor levels of PLD activity in cells where FcRI is not aggregated; XL,
aggregation. PLD activity was measured using the PLD activity in cells following FcRI receptor aggregation. Bottom
transphosphatidylation accumulation assay [4]. XL control, FcRI panel, Western blot for PKC in control cells and cells treated with
aggregated in cells not treated with either inhibitor. Results are the the antisense oligonucleotide to PKC.
mean  SD for triplicate measurements and are representative of
of PKC kinase activity, supporting the concept that PLD generated by crosstalk between ARF6 and PKC inde-
pendent of PKC kinase activity.is regulated through a physical interaction with PKC
and rather than kinase activity. These data imply that
coupling of FcRI to PLD1 activation requires signals In IFN--primed U937 cells, FcRI is known to be cou-
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Figure 3
PLD1 and not PLD2 lies upstream of FcRI-mediated activation of PLD2 did not. Cells were pretreated with either antisense to PLD1
PKC activity. (a) Preincubation of cells with 0.3% butan-1-ol inhibits or antisense to PLD2 for 36 hr prior to receptor aggregation and
the activation of PKC following FcRI aggregation, whereas butan- measurement of PKC activity at the times indicated. Basal, resting
2-ol did not. Cells were pretreated with either 0.3% butan-1-ol (but- cells; XL, FcRI aggregation; control, untreated cells; a.s.PLD1,
1-ol) or 0.3% butan-2-ol (but-2-ol) for 20 min prior to receptor treatment with antisense to PLD1; a.s.PLD2, treatment with antisense
aggregation and measurement of PKC activity at the times indicated to PLD2. Results are the mean  SD for triplicate measurements
[4]. XL control, FcRI aggregated in cells not treated with alcohol. and are representative of the results from at least three separate
Results are the mean  SD for triplicate measurements and are experiments. (d) Downregulation of PLD1 by antisense treatment
representative of the results from at least three separate experiments. inhibited the translocation of PKC isoforms to the nuclear-free
(b) Western blot analysis of PKC, -, and - isoenzymes in the nuclear- membrane fraction following FcRI aggregation, whereas
free membrane fraction. Cells were pretreated with either 0.3% butan- downregulation of PLD2 did not. Cells were harvested at various times
1-ol or 0.3% butan-2-ol for 20 min prior to receptor aggregation. after receptor aggregation, lysed, and the nuclear-free membrane fraction
Cells were harvested at various times after receptor aggregation, lysed, was prepared. After SDS-PAGE and transfer to nitrocellulose, the
and the nuclear-free membrane fraction prepared. After SDS-PAGE blots were probed with monoclonal antibodies against the three
and transfer to nitrocellulose, the blots were probed with monoclonal PKC isoforms previously identified to translocate following FcRI
antibodies against the three PKC isoforms previously identified to aggregation, namely, PKC, -, and -. Control, untreated cells;
translocate following FcRI aggregation, namely, PKC, -, and - [8]. a.s.PLD1, treatment with antisense to PLD1; a.s.PLD2, treatment with
The results shown are typical from three separate experiments. (c) antisense to PLD2. The results shown are typical from three separate
Downregulation of PLD1 by antisense treatment inhibited the activation experiments
of PKC following FcRI aggregation, whereas downregulation of
pled to an increase in PKC activity that is calcium inde- was measured following FcRI aggregation in cells pre-
treated with either butan-1-ol (0.3%) or with butan-2-olpendent but lipid dependent, and the isozymes , , and
 have been shown to translocate to themembrane, follow- (0.3%). Butan-1-ol but not butan-2-ol can act as an ac-
ceptor for the phosphatidyl moiety, thereby generatinging receptor aggregation by immune complexes [8]. Hav-
ing shown that PKC kinase activity is not required to phosphatidyl butanol instead of phosphatidic acid [4]. As
butan-2-ol cannot act as an acceptor, it serves as a controlcouple FcRI to PLD activation, we next investigated
the dependence of PKC activation on the generation of for nonspecific effects of the alcohol. Activation of PKC
was abolished in cells treated with 0.3% butan-1-ol butphosphatidic acid following PLD activation. PKC activity
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not in those treated with 0.3% butan-2-ol (Figure 3a). antisense oligonucleotide, therefore, acted as an internal
control for the other.These data indicate that PLD is necessary for the coupling
of FcRI to the activation of PKC and that, perhaps sur-
prisingly, all FcRI-stimulated PKC activity lies down- Specific downregulation of PLD1 by treating cells with
stream of PLD activation. the antisense to PLD1 attenuated FcRI-coupled PKC
activity (Figure 3c) and reduced translocation of PKC,
-, and - (Figure 3d). Specific downregulation of PLD2To confirm this finding and to assess PKC isozyme speci-
with the corresponding antisense oligonucleotide to PLD2ficity in more detail, the effect on receptor-coupled PKC
had no effect on PKC activity or isozyme translocation.translocation to the membrane was assessed in cells incu-
Therefore, PLD1 and not PLD2 appears to couple FcRIbatedwith 0.3% butan-1-ol comparedwith cells incubated
to the activation of PKCs and, consistent with the findingswith the same concentration of butan-2-ol. Translocation
described above, FcRI activation of PKC activity inof the three PKCs, , , and , was abolished in cells
these cells appears to be dependent on and lie down-pretreated with 0.3% butan-1-ol but not in cells preincu-
stream of PLD activation.bated with butan-2-ol (Figure 3b). Thus, the three PKC
isozymes known to translocate to themembrane following
In summary, we have shown here that activation of theFcRI aggregation are dependent on PLD-derived phos-
receptor FcRI by surface immune complexes on IFN-phatidic acid. PKC is found to be constitutively present
-primed U937 cells stimulates the association of PLD1in the membrane fraction in these cytokine-primed cells,
with ARF6 and PKC independent of PKC kinase activ-and no further translocation can be observed following
ity. All the observed FcRI-mediated increase in PKCFcRI aggregation [8].
activity requires PLD1 isozyme activity. PLD activation
generates a variety of intracellular signaling molecules.The regulatory domains of PKCs are diverse; different
The activation of different PKC isozymes downstream ofisozymes are likely to influence PLD activity to varying
PLD activation through potentially different mechanismsdegrees. The role of the novel and atypical PKCs in regu-
provides evidence for the generation of diverse responseslating PLD has not been defined, and our data here indi-
in this system. The potential diversity offers the opportu-cate that PKC, -, and - do not play a role. Rather,
nity within the cell to regulate very precisely differentialwe show here that all FcRI-mediated PKC activity was
signal transduction cascades.dependent on PLD-derived phosphatidic acid, indicating
that PLD activity lies upstream of PKC activity in these Supplementary material
cells. Previous studies have shown a large PLD-depen- Supplementary material including the materials and methods for the
dent surge in intracellular DAG following FcRI aggrega- present study and figures showing Western blot analysis on the downreg-
ulation in PLD1 and PLD2 protein expression by antisense treatmenttion [17]. PKC and - are both novel PKCs and are thus
and showing that downregulation of PLD1 and not PLD2 attenuates theregulated by DAG, and it seems likely that this surge in
increase in PLD activity observed after aggregation of FcRI is available
DAG activates the novel PKCs. However, the DAG spe- at http://images.cellpress.com/supmat/supmatin.htm.
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